IONQ
IONQ
$34.06
-2.66%
IonQ, Inc. is a pure-play quantum computing company that sells cloud-based access to its trapped-ion quantum computers through quantum-computing-as-a-service (QCaaS) arrangements, while also generating revenue from consulting engagements, algorithm co-development, and bespoke contracts for the design and construction of specialized quantum systems. As one of the few publicly listed pure-play quantum hardware vendors, IonQ positions itself as a technology leader in trapped-ion architectures rather than a diversified platform incumbent, competing against superconducting approaches from IBM and Google as well as other pure-plays such as Rigetti and D-Wave. The current investor narrative is dominated by an aggressive, acquisition-led expansion strategy — most notably a roughly $1.3 billion all-stock deal (reported around the Elisity transaction) and a $2 billion capital raise — which investors have greeted with heavy skepticism over dilution, driving a sharp share-price decline even as sell-side analysts maintain a strongly bullish stance. Debate now centers on whether IonQ can convert its large cash pile and expanding technical roadmap into durable commercial revenue before dilution and cash burn erode the equity story.…
IONQ
IONQ
$34.06
Related headlines
Investment Opinion: Should I buy IONQ Today?
Rating: Hold (speculative, high-risk). The core thesis is that IonQ's fortress balance sheet (debt-to-equity of 0.0079, current ratio of 15.50) and a sell-side consensus of 12 Buys versus 0 Sells with a $60.275 average target (+84.8% upside from $32.62) buy the company time and optionality, but a 96.75x trailing PS multiple, a -487.4% operating margin, and accelerating dilution from the ~$1.3 billion Elisity all-stock deal and $2 billion raise mean the equity story is being eroded faster than revenue can validate it. The risk/reward is asymmetric only for investors who can tolerate a -67.8% historical max drawdown and a -23.6% retest of the $24.915 52-week low.
Supporting evidence is mixed but tilts toward patience rather than aggressive accumulation. On the positive side, quarterly revenue stepped up from $64.67 million in Q1 2026 to $80.05 million in Q2 and $173.83 million in Q3 (a 3.36% YoY comparison against Q3 2025's $39.87 million), price-to-book of 3.31x sits near the bottom of its historical 1.2x-23.7x band, and the stock's 15.9% position in its 52-week range means much of the dilution and execution risk is already priced in. Against that, gross margin compressed to 21.88% from 56.48% in Q4 2025, trailing free cash flow is -$688.54 million, Q3 stock-based compensation alone was $146.91 million, and the headline $563.96 million net income was entirely an $854.49 million non-operating gain — the underlying business remains deeply unprofitable with no earnings-based valuation anchor (negative PEG of -1.48).
The biggest risks that could invalidate even a Hold are a Q4 revenue miss against the ~$2.25 billion forward consensus (range $1.97-$2.65 billion), a stumble in Elisity integration that forces another equity raise, and continued multiple compression if rates stay elevated and capital rotates out of pre-revenue names. This Hold would upgrade to Buy if the stock holds above the $30-31 congestion zone and Q4 revenue confirms the sequential acceleration with gross margin recovering above 30%, or downgrade to Sell on a decisive break below the $24.915 52-week low or a revenue miss that pushes the PS multiple toward the low end of its historical band without a corresponding growth inflection. Valuation verdict: fairly valued relative to its own compressed history but still at a several-hundred-percent premium to hardware peers — the market is paying today for revenue that may not arrive until 2027 and beyond.
Sign up to view all
IONQ 12-Month Price Forecast
IonQ presents a genuinely bifurcated setup: the sell-side is uniformly constructive with a $60.275 average target implying +84.8% upside and no published target below the current price, yet the market has voted with a -43.20% one-year decline, -21.09% one-month slide, and a -67.8% max drawdown that leaves the stock at just 15.9% of its 52-week range. The tension is that the 96.75x PS multiple can only be justified by the ~$2.25 billion forward revenue consensus — roughly 6x growth from trailing levels — while the -487.4% operating margin, 21.88% gross margin, and accelerating dilution from the Elisity deal and $2 billion raise argue the equity story is being eroded faster than revenue can validate it. The +23.42% one-day bounce on 42.9 million shares off the $24.915 low is a hopeful sign but not a confirmed reversal, and with a short ratio of only 1.84 there is limited squeeze fuel to sustain it. I would upgrade to bullish if Q4 revenue confirms the sequential acceleration with gross margin recovering above 30% and the stock holds above the $30-31 congestion zone, and downgrade to bearish on a decisive break below $24.915 or a revenue miss that compresses the multiple without a growth inflection.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IONQ's 12-month outlook, with a consensus price target around $54.27 and implied upside of +59.4% versus the current price.
Average Target
$54.27
14 analysts
Implied Upside
+59.4%
vs. current price
Analyst Count
14
covering this stock
Price Range
$40 - $70
Analyst target range
Coverage is robust for a company of this profile, with 14 analysts publishing ratings and a distribution of 12 Buy, 2 Hold, and 0 Sell, yielding a consensus recommendation of 'strong_buy' (mean rating 1.36 on a 1-5 scale). The average target price of $60.275 implies roughly +84.8% upside from the current $32.62, a strikingly bullish signal that stands in sharp contrast to the stock's -43.20% one-year performance and -21.09% one-month decline. The consensus clearly leans bullish, and the recent institutional ratings flow reinforces this — Needham, Cantor Fitzgerald, B. Riley, Rosenblatt, and Wedbush have all reiterated Buy/Overweight/Outperform ratings through October and November 2026, with Morgan Stanley the notable Equal Weight hold. The wide gap between the consensus target and the market price suggests analysts are anchoring on long-term quantum commercialization and the $2.25 billion forward revenue estimate rather than near-term dilution and cash-burn realities. The target range spans $40.00 to $75.00 — a spread of $35.00, or roughly 107% of the current share price — signaling high uncertainty and low conviction in point estimates. The $75.00 high target likely assumes successful integration of the $1.3 billion acquisition, accelerating QCaaS and system-sales revenue toward the consensus $2.25 billion, and multiple expansion as quantum commercialization milestones are hit; the $40.00 low target — still 22.6% above the current price — appears to price in continued dilution, margin compression from hardware-heavy revenue mix, and a longer path to profitability without a full de-rating. Notably, even the most bearish published target sits above the current price, implying analysts view the post-selloff level as oversold relative to fundamentals, though the persistent reiteration (rather than upgrading) pattern and the absence of any downgrades suggests analysts are holding steady rather than turning more constructive — a stance that leaves the stock vulnerable if Q4 results disappoint.
Drowning in data?
Find the real signal!
Bulls vs Bears: IONQ Investment Factors
The bear case currently has stronger near-term evidence: a -43.20% one-year decline, -487.4% operating margin, 96.75x sales multiple, and accelerating dilution from the $1.3 billion Elisity deal and $2 billion raise all argue the equity story is being eroded faster than revenue can validate it. The bull case rests on a fortress balance sheet (0.0079 debt-to-equity, 15.50 current ratio), a genuine sequential revenue inflection to $173.83 million in Q3, and a sell-side consensus that is uniformly constructive — 12 Buys, 0 Sells, $60.275 average target implying +84.8% upside. The single most important tension is whether IonQ can convert its cash pile and expanding technical roadmap into durable commercial revenue before dilution and cash burn erode the equity story; if the ~$2.25 billion forward revenue estimate proves achievable, the current 96.75x PS is defensible, but if growth stalls, the multiple has nowhere to go but down. The recent +23.42% one-day bounce is a hopeful sign but not yet a confirmed reversal, and the stock remains a high-risk, high-reward speculative position where the balance sheet buys time but does not guarantee the thesis.
Bullish
- Analyst consensus overwhelmingly bullish: 12 of 14 analysts rate IONQ a Buy with zero Sells, yielding a 'strong_buy' consensus (mean rating 1.36). The $60.275 average target implies +84.8% upside from $32.62, and even the most bearish published target of $40.00 sits 22.6% above the current price.
- Fortress balance sheet, near-zero debt: Debt-to-equity is just 0.0079 and the current ratio is 15.50, giving IonQ essentially no solvency risk. The $2 billion capital raise and remaining cash/investments provide multi-year runway to fund the roadmap even against a -$688.54 million trailing free cash flow burn.
- Revenue inflecting sharply sequentially: Quarterly revenue jumped from $64.67 million in Q1 2026 to $80.05 million in Q2 and $173.83 million in Q3, a 3.36% YoY step-up versus Q3 2025's $39.87 million. The consensus forward revenue estimate of ~$2.25 billion implies roughly 6x growth from trailing levels, and the trajectory shows the company is at least moving in that direction.
- Valuation compressed to low end of history: Price-to-book of 3.31x sits near the bottom of its historical 1.2x-23.7x band, and PS has fallen from 1,946x in Q4 2021 to 96.75x today. The -67.8% max drawdown and 15.9% position in the 52-week range mean much of the dilution and execution risk is now priced in.
Bearish
- Extreme 96.75x sales valuation: At 96.75x trailing PS (34.72x EV/Sales) on ~$360 million of revenue, IonQ trades at several hundred percent premium to hardware peers at low-single-digit multiples and even high-growth semis at 15-20x. There is essentially no margin for execution error, and any revenue miss would likely trigger another leg of multiple compression.
- Massive dilution from acquisition strategy: The ~$1.3 billion all-stock Elisity deal and $2 billion capital raise have been greeted with heavy selling — the stock fell 10% on the Elisity news alone. Shares outstanding rose from 294.5 million in Q3 2025 to 388.6 million in Q3 2026, and stock-based compensation alone was $146.91 million in Q3, making dilution the primary financial risk.
- Operating losses and margin collapse: Q3 2026 operating income was -$433.08 million with an operating margin of -487.4%, and gross margin compressed to 21.88% from 56.48% in Q4 2025. The headline $563.96 million net income and $1.42 EPS were entirely driven by an $854.49 million non-operating gain, not the underlying business.
- Severe downtrend and relative weakness: IONQ is down 43.20% over one year, 30.25% YTD, and 21.09% over the past month versus the S&P 500's -4.99%, producing a -52.79% one-year relative strength reading. The stock sits deep in the lower quartile of its 52-week range with a -67.8% max drawdown, a classic 'falling knife' profile.
IONQ Technical Analysis
IonQ is locked in a pronounced, sustained downtrend, with the stock down 43.20% over the trailing year and 30.25% year-to-date, a stark underperformance versus the S&P 500's +9.59% one-year return (relative strength of -52.79%). At the current price of $32.62, the shares sit at roughly 15.9% of the 52-week range between a $24.915 low and a $73.65 high — deep in the lower quartile of the band, which signals persistent distribution and a 'falling knife' profile rather than a clean value entry. The maximum drawdown of -67.8% underscores how severely the stock has de-rated from its highs, and the 52-week high of $73.65 now stands more than 125% above the current price, illustrating the magnitude of the round-trip. Recent momentum remains decisively negative and is diverging from the longer-term trend only in its severity: the stock is down 21.09% over the past month and 26.58% over three months, both far worse than the S&P 500's -4.99% and -4.91% respective moves, producing relative strength readings of -16.10 (1-month) and -21.67 (3-month). The one-month decline of -21.09% is steeper than the three-month -26.58% pace on an annualized basis, indicating momentum is still accelerating to the downside rather than stabilizing. The single most notable data point is the +23.42% one-day surge on the latest session (from a $26.43 previous close to $32.62) on elevated volume of 42.9 million shares — a violent counter-trend bounce that, in the context of a -67.8% drawdown, looks more like short-covering or news-driven relief than a confirmed reversal; traders should watch whether this spike holds above the prior $30-31 congestion zone. Key technical levels are well defined: support rests at the $24.915 52-week low, and a breakdown below that level would signal a fresh leg lower and likely trigger momentum-driven selling, while resistance sits at the $73.65 high with intermediate supply clustered in the $40-45 area where the stock repeatedly failed in August and September. With a short ratio of only 1.84, there is limited short-squeeze fuel to sustain rallies, and while beta is not provided, the -67.8% drawdown and 23% single-day swings imply volatility far in excess of the market, demanding materially smaller position sizing and wider stops for any risk-managed exposure.
Beta
3.41
3.41x market volatility
Max Drawdown
-67.8%
Largest decline past year
52-Week Range
$25-$74
Price range past year
Annual Return
-37.4%
Cumulative gain past year
| Period | IONQ Return | S&P 500 |
|---|---|---|
| 1m | -6.1% | -2.4% |
| 3m | -24.3% | -2.3% |
| 6m | -34.4% | +2.8% |
| 1y | -37.4% | +11.3% |
| ytd | -27.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IONQ Fundamental Analysis
Revenue is growing but from a very small base and with lumpy optics: Q3 2026 revenue of $173.83 million represented 3.36% year-over-year growth versus Q3 2025's $39.87 million, a dramatic step-up that reflects both organic expansion and the consolidation of acquired businesses. The multi-quarter trajectory shows $64.67 million in Q1 2026, $80.05 million in Q2, and $173.83 million in Q3 — a sharp sequential acceleration that is encouraging but heavily influenced by inorganic contributions and large system-sales contracts rather than recurring QCaaS demand. The consensus forward revenue estimate of approximately $2.25 billion (range $1.97 billion to $2.65 billion) implies the market expects another order-of-magnitude leap, so the investment case hinges entirely on execution against an extremely aggressive growth curve. Profitability is deeply negative on an operating basis despite headline GAAP profits: Q3 2026 net income of $563.96 million and EPS of $1.42 were driven by a $854.49 million non-operating gain (total other income), while operating income was -$433.08 million and the operating margin stood at -487.4%. Gross margin has compressed to 21.88% in Q3 2026 from 56.48% in Q4 2025 and 47.99% in Q3 2025, a deterioration consistent with a hardware-heavy, lower-margin systems mix; the trailing net margin of -392.6% and ROE of -13.43% confirm the underlying business remains unprofitable. The balance sheet is the company's strongest asset: a current ratio of 15.50, debt-to-equity of just 0.0079, and $217.01 million in cash at quarter-end (down from $1.24 billion after $894.44 million of acquisitions and $700 million of investment purchases) provide substantial runway, though the burn is real — trailing free cash flow is -$688.54 million and Q3 operating cash flow was -$315.54 million. Stock-based compensation of $146.91 million in Q3 alone and heavy reliance on equity issuance (nearly $1.95 billion of common stock issued in Q4 2025) mean dilution, not debt, is the primary financial risk; the near-zero leverage is reassuring for solvency but does not offset the cash-consumption profile.
Quarterly Revenue
$173831000.0B
2026-09
Revenue YoY Growth
+336.0%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$-688541000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IONQ Overvalued?
Because IonQ's trailing net income is technically positive but entirely driven by non-operating gains (operating income is deeply negative and trailing EPS is -$0.04), the PE ratio of -24.65x is not meaningful; the appropriate primary metric is the price-to-sales ratio of 96.75x, supplemented by EV/Sales of 34.72x. The forward PE of -26.39x versus trailing -24.65x offers no normalization signal since both are negative, and the negative PEG of -1.48 confirms there is no earnings-based valuation anchor — the market is pricing this stock purely on future revenue optionality. A 96.75x sales multiple on roughly $360 million of trailing revenue implies investors are capitalizing a multi-year hyper-growth scenario, and the gap between the 96.75x trailing PS and 34.72x EV/Sales reflects the large net cash and investment position embedded in enterprise value. Against a hardware/technology peer set where mature computer hardware companies trade at low-single-digit sales multiples and even high-growth semiconductor names rarely exceed 15-20x, IonQ's 96.75x PS represents a premium of several hundred percent — a spread that can only be justified by the consensus forecast of ~$2.25 billion in forward revenue, which itself implies roughly 6x growth from current levels. Historically, IonQ's PS ratio has compressed dramatically from 1,946x in Q4 2021 and 777x in Q4 2024 to 96.75x today, a decline driven by revenue growth rather than multiple expansion; however, the stock's price-to-book of 3.31x sits near the low end of its historical 1.2x-23.7x band, suggesting the recent selloff has compressed the valuation toward the cheaper end of its own range. The tension is that even at the low end of its historical PS band, 96.75x sales leaves essentially no margin for execution error, and any revenue miss or further dilution would likely trigger another leg of multiple compression.
PE
-24.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
18.5x
Industry PE ~18.5x*
EV/EBITDA
-24.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by cash consumption and dilution rather than leverage. Trailing free cash flow is -$688.54 million and Q3 operating cash flow was -$315.54 million, while stock-based compensation alone reached $146.91 million in the quarter and shares outstanding expanded from 294.5 million to 388.6 million year-over-year. Gross margin has compressed to 21.88% from 56.48% in Q4 2025 as the revenue mix shifts toward lower-margin hardware and system sales, and the -487.4% operating margin confirms the core business is deeply unprofitable despite headline GAAP net income of $563.96 million that was entirely driven by an $854.49 million non-operating gain. Revenue is also concentrated in lumpy bespoke system-sales and consulting contracts rather than recurring QCaaS, making quarterly results highly volatile and dependent on a handful of large deals. Market and competitive risks center on valuation compression and the quantum arms race. At 96.75x trailing PS and 34.72x EV/Sales, IonQ trades at a several-hundred-percent premium to hardware peers, and the stock's beta is not provided but its -67.8% max drawdown and 23% single-day swings imply volatility far in excess of the market. Competition is intensifying from IBM and Google's superconducting approaches as well as pure-plays Rigetti, D-Wave, and Xanadu, and recent news highlights that Xanadu's GlobalFoundries manufacturing partnership and D-Wave's operational momentum are credible competitive milestones. Regulatory and geopolitical headwinds around export controls on quantum technology, plus sector rotation out of speculative pre-revenue names if rates stay elevated, could compress the multiple further regardless of company execution. The worst-case scenario is a chain in which Q4 results miss the aggressive ~$2.25 billion forward revenue trajectory, the Elisity integration stumbles, and another equity raise is required — triggering analyst downgrades and a fresh leg of multiple compression. Quantitatively, a retest of the $24.915 52-week low would represent roughly -23.6% from the current $32.62, and a break below that level could extend toward the low-$20s, implying a -30% to -40% drawdown; the -67.8% historical max drawdown shows how severe the tail can be. Even the most bearish published analyst target of $40.00 is above the current price, so the downside here is technical and sentiment-driven rather than reflected in sell-side estimates.
FAQ
The most severe risk is dilution: the ~$1.3 billion all-stock Elisity deal and $2 billion raise expanded shares outstanding from 294.5 million to 388.6 million year-over-year, and Q3 stock-based compensation alone was $146.91 million. Second is cash burn and profitability — trailing free cash flow is -$688.54 million, Q3 operating cash flow was -$315.54 million, and the -487.4% operating margin means the headline $563.96 million net income was entirely an $854.49 million non-operating gain. Third is valuation compression: at 96.75x PS, any revenue miss or sector rotation out of speculative pre-revenue names if rates stay elevated could trigger another leg down. Fourth is competitive and execution risk — IBM, Google, Rigetti, D-Wave, and Xanadu are all advancing, and the ~$2.25 billion forward revenue target requires an order-of-magnitude leap that depends on lumpy system-sales contracts rather than recurring QCaaS demand. Ranked by severity: dilution, cash burn, valuation compression, then competition.
The three-scenario framework assigns a 55% probability to the base case, a 25% bear case, and a 20% bull case. The base case targets $40.00-$60.00, assuming revenue grows but lands below the $2.25 billion consensus midpoint, no new equity raise, gross margin stabilizing in the low-to-mid 20s, and analysts reiterating rather than upgrading. The bear case targets $24.915-$40.00, driven by a Q4 revenue miss, Elisity integration stumbles, another raise, and downgrades from the 12 Buy ratings. The bull case targets $60.00-$75.00, requiring successful Elisity integration, accelerating QCaaS and system-sales revenue validating the consensus, and gross margin recovery above 30%. The base case is most likely, and its key assumption is that IonQ grinds sideways to modestly higher without a growth inflection — the stock stays range-bound between the $30-31 support and $40-45 supply zone.
On the primary metric, IONQ is expensive in absolute terms but cheaper than its own history. The 96.75x trailing PS and 34.72x EV/Sales compare to hardware peers at low-single-digit multiples and high-growth semis at 15-20x, a premium of several hundred percent that can only be justified by the ~$2.25 billion forward revenue consensus — roughly 6x growth from trailing levels. However, PS has compressed from 1,946x in Q4 2021 and 777x in Q4 2024 to 96.75x today, and price-to-book of 3.31x sits near the bottom of its 1.2x-23.7x historical band. The negative PE (-24.65x) and PEG (-1.48) mean there is no earnings-based anchor, so the market is pricing pure revenue optionality. The verdict is fairly valued relative to its own compressed history but still at a steep premium to peers — the market is paying today for revenue that may not arrive until 2027 and beyond.
From a pure risk/reward standpoint, IONQ offers an asymmetric setup only for investors who can stomach extreme volatility. The $60.275 average analyst target implies +84.8% upside from $32.62, and even the most bearish published target of $40.00 sits 22.6% above the current price, suggesting the sell-side views the post-selloff level as oversold. Against that, the stock has fallen 43.20% over one year with a -67.8% max drawdown, and a retest of the $24.915 52-week low would mean roughly -23.6% from here. The biggest downside risk is a Q4 revenue miss against the ~$2.25 billion forward consensus that compresses the 96.75x PS multiple without a growth inflection. It is a reasonable speculative buy only for risk-tolerant investors with a multi-year horizon and position sizes small enough to absorb a -30% to -40% drawdown; it is not suitable for capital-preservation or income-oriented portfolios.
IONQ is a long-term speculative holding, not a short-term trading vehicle for most investors. The company is early-stage with a -487.4% operating margin, negative free cash flow of -$688.54 million, and no dividend, so there is no earnings or income visibility to anchor near-term price — the stock's 23% single-day swings and -67.8% max drawdown demand wide stops and small position sizes for any tactical exposure. The bull thesis depends on quantum commercialization milestones and the ~$2.25 billion forward revenue consensus materializing, which is a multi-year path rather than a quarterly trade. A concrete suggested minimum holding period is 3-5 years, sized as a small satellite position, with the understanding that the fortress balance sheet (current ratio 15.50, debt-to-equity 0.0079) buys time but does not guarantee the thesis. Short-term traders should treat the $30-31 congestion zone and $24.915 low as hard risk levels.